Therefore, targeting IFNAR1 down-regulation is potentially an effective approach to bypass both PD-L1-depedent and PD-L1-independent immune suppressions to directly activate CTL effector function to suppress colon carcinoma growth. This evidence concerns the gene IFNAR1 and colon carcinoma.